Navigation Links
Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
Date:2/6/2008

-- Study concludes there was no evidence of the development of viral resistance to R7128 after 2 weeks of monotherapy in hepatitis C patients --

PRINCETON, N.J., Feb. 6 /PRNewswire-FirstCall/ -- Pharmasset (Nasdaq: VRUS) and Roche will present the R7128 monotherapy resistance profile at the EASL-AASLD-APASL-ALEH-IASL Conference on Hepatitis B & C Virus Resistance to Antiviral Therapies being held in Paris, France from February 14-16, 2008. The scientific abstract for poster board no. 36, entitled "Lack of Viral Resistance after 14-day Monotherapy Treatment with R7128 in Treatment-experienced Patients Infected with HCV Genotype 1," is currently available on the conference website at http://www.easl.ch/hepatitis-conference/program/session1.asp. The poster presentation will be available for download in PDF format after it is presented on February 14, 2008 in the "Events & Presentations" section of Pharmasset's website at http://investor.pharmasset.com/events.cfm.

About R7128

R7128 is being developed for the treatment of chronic HCV infection through Pharmasset's collaboration with Roche. R7128 is a prodrug of PSI-6130, a nucleoside analog inhibitor of HCV RNA polymerase. A prodrug is a chemically modified form of a molecule designed to enhance the absorption, distribution and metabolic properties of that molecule.

In a Phase 1 clinical trial, R7128 demonstrated potent, dose-dependent antiviral activity across four patient cohorts (n=40) receiving 750mg or 1500mg administered either once-daily or twice-daily for 2 weeks as monotherapy. The greatest mean decrease in HCV RNA from baseline was observed in the patient cohort that received 1500mg twice-daily, the highest dose of R7128 administered in the study. These patients experienced a mean 2.7 log10 IU/mL (>99%) decrease in HCV R
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Roche responds to announcement of IDEAL hepatitis C trial results
2. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
3. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
4. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
5. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
6. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
7. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
8. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
9. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
10. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
11. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/6/2009)...6 The Michael J. Fox Fo...four industry research teams for pre-clinical rese...isease. , , The funding was awarded under the F... This program, first launched in 2006, supports an... research. TDI is part of MJFF,s focus on ,de-...
(Date:1/5/2009)... 5 Cylene Pharmaceuticals announce...rial of its oral CK2 protein kinase inhibitor, CX-...leman,s disease, or multiple myeloma. The primary ...termination of safety, tolerance and PK properties... Phase II trials. In addition, multiple mechanism-...
(Date:12/29/2008)...Dec. 29 The winner of t...tection was announced today by Dr. Peter G. Goldsc...ment Institute. , , The winner of the annual a... Cancer Center -- for its best practice " IND Re...ovides for 1) enhanced human subjects protection, ...
(Date:12/17/2008)... show for the first time that normal stem cells ca...ues , , MEMPHIS, Tenn., Dec. 17 /PRNewswire...s Research Hospital have answered a central questi...n give rise to tumors. Stem cells are immature cel...re differentiated cells that compose the range of ...
Breaking Medicine Technology:Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinson's Disease Research 2Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 2Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 32008 Human Research Protection Award Recipients Announced 2Molecular Marker Identifies Normal Stem Cells as Intestinal Tumor Source 2Molecular Marker Identifies Normal Stem Cells as Intestinal Tumor Source 33 D photonic crystals will revolutionize telecommunications 1888 13 D photonic crystals will revolutionize telecommunications 1888 23 D photonic crystals will revolutionize telecommunications 1888 3Acting Surgeon General Encourages Americans to Know Their Health History During Fourth Annual Family History Day 6757 1Acting Surgeon General Encourages Americans to Know Their Health History During Fourth Annual Family History Day 6757 2Acting Surgeon General Encourages Americans to Know Their Health History During Fourth Annual Family History Day 6757 3MEDRAD Mobile MR Injector Meets Challenges of MR Trailers 6755 1MEDRAD Mobile MR Injector Meets Challenges of MR Trailers 6755 2Franklin 26 Seidelmann Adds 31 Subspecialty Radiologists to Support Growing Demand for Subspecialty Expertise 6753 1Franklin 26 Seidelmann Adds 31 Subspecialty Radiologists to Support Growing Demand for Subspecialty Expertise 6753 2Franklin 26 Seidelmann Adds 31 Subspecialty Radiologists to Support Growing Demand for Subspecialty Expertise 6753 3Franklin 26 Seidelmann Adds 31 Subspecialty Radiologists to Support Growing Demand for Subspecialty Expertise 6753 4Franklin 26 Seidelmann Adds 31 Subspecialty Radiologists to Support Growing Demand for Subspecialty Expertise 6753 5Franklin 26 Seidelmann Adds 31 Subspecialty Radiologists to Support Growing Demand for Subspecialty Expertise 6753 6Franklin 26 Seidelmann Adds 31 Subspecialty Radiologists to Support Growing Demand for Subspecialty Expertise 6753 7Franklin 26 Seidelmann Adds 31 Subspecialty Radiologists to Support Growing Demand for Subspecialty Expertise 6753 8
(Date:1/8/2009)...ber Tom Torlakson Introduces AB 89 , , SACRAMEN...day, Lung Cancer Alliance-California (LCA-CA), hai...th District) for his continued leadership in intro...er research. For the third consecutive year, legi...ing considered in the California Legislature. ,...
(Date:1/8/2009)...dy could shape new treatments for secondary pneumo...wswire/ -- Scientists at St. Jude Children,s Resea...eatment for bacterial pneumonia following influenz... azithromycin, which kill bacteria by inhibiting t...standard first-line treatment with the "beta-lacta...
(Date:1/8/2009)...n hurtful comments, study suggests , , ...verestimate how strongly they would react to racis...ee percent of study participants at York Universit...iment with a white person rather than a black one,...about the black person when he left the room. ,...
(Date:1/8/2009)...ildren,s Research Hospital have demonstrated a mor...owing influenza. They found that the antibiotics c...y inhibiting their protein synthesis, are more eff...he "beta-lactam" antibiotic ampicillin, which caus...ng is important because pneumonia, rather than the...
Breaking Medicine News(10 mins):Health News:Lung Cancer Alliance Applauds New Legislation Funding Lung Cancer Research 2Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 2Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 3Health News:Many Turn Blind Eye to Racism 2Health News:Study finds more effective treatment for pneumonia following influenza 2Health News:Study finds more effective treatment for pneumonia following influenza 3
... had reported that the blood samples of autistic c...nents of the immunity system. This may be the firs... the blood tests of children. Autism spectrum diso... seen in a mild to the most sever form. The charac...
...hers say cholesterol may be actually needed to hel...ever researchers also say that too much of it coul...eries, where it builds up as plaque and can cause ...uggest an enzyme called ACAT2 may be to blame for ...
...regnancy not only decides the health// of the fetu...n as well. In a study to understand fetal developm...und out about long-term influence on the genetic c...ealth of the next few generations. Their research ...
... UK, has provided new guidelines //for dealing wit...uidelines suggest that psychological therapy be gi...ral or man made is always tough. NICE had emphasiz...thing shelter to these traumatized people it is al...
Other Medicine News:
Vannas Capsulotomy scissors angled
Gills-Vannas straight capsulotomy flat handle scissors
Vannas angled capsulotomy round handle scissors
Solid blade speculum designed for both temporal and superior approach ocular surgery. Adjustable with thumb screw. Manufactured in titanium.
Medicine Products: